Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xbrane Biopharma AB (FRA:7XB0) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Xbrane Biopharma AB's Enterprise Value for the quarter that ended in Jun. 2026 was €19.72 Mil.
Xbrane Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xbrane Biopharma AB EV-to-EBIT Related Terms
Xbrane Biopharma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Xbrane Biopharma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7XB0 vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Xbrane Biopharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xbrane Biopharma AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xbrane Biopharma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Xbrane Biopharma AB's EV-to-EBIT falls into.
Xbrane Biopharma AB's current Enterprise Value is €18.42 Mil.
Xbrane Biopharma AB's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xbrane Biopharma AB (FRA:7XB0) has a EV-to-EBIT of -2.97 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xbrane Biopharma AB and its competitors. According to the industry distribution chart, Xbrane Biopharma AB ranks #999999 out of 380 companies in the Biotechnology industry.
Is Xbrane Biopharma AB's EV-to-EBIT too high?
Xbrane Biopharma AB's current EV-to-EBIT is -2.97. Based on the distribution chart, Xbrane Biopharma AB ranks #999999 out of 380 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Xbrane Biopharma AB has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Xbrane Biopharma AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xbrane Biopharma AB ranks #999999 out of 380 companies for EV-to-EBIT. This places Xbrane Biopharma AB in the lower half of its industry. The industry median EV-to-EBIT is 15.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.86, based on 380 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Xbrane Biopharma AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xbrane Biopharma AB's current EV-to-EBIT is -2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xbrane Biopharma AB stock overvalued right now?
Xbrane Biopharma AB (FRA:7XB0) has a current EV-to-EBIT of -2.97. The stock's GF Value™ is €0.49, compared to a current price of €0.77 — trading 57.6% above its estimated fair value. The current EV-to-EBIT is -2.97. Xbrane Biopharma AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Xbrane Biopharma AB (FRA:7XB0), the current EV-to-EBIT is -2.97 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xbrane Biopharma AB (FRA:7XB0) Overvalued in 2026?
Based on GuruFocus' analysis, Xbrane Biopharma AB stock appears to be overvalued.
The current stock price of €0.77 is trading 57.6% above its estimated GF Value™ of €0.49.
Key valuation signals for FRA:7XB0:
EV-to-EBIT: -2.97
GF Value™: €0.49 vs. price of €0.77 (57.6% above fair value)
No single metric tells the full story. See the FRA:7XB0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xbrane Biopharma AB is a biotechnology company that develops biosimilars. The company follows drugs on already approved biological drugs that can be introduced at a lower price after the patent expires on the original drug. The company has a patented protein production platform with greater productivity than standard systems for producing proteins in E.coli host cells. The company's product candidate is Ximluci, a ranibizumab biosimilar (original drug Lucentis) used in the treatment of various eye diseases, mainly the wet form of age-related macular degeneration. Other products in preclinical stage of the company includes Xdivane and Xdarzane.
71GF Score
Get the complete analysis for FRA:7XB0
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7XB0 has been successfully added to your 
